{
    "clinical_study": {
        "@rank": "60387", 
        "arm_group": [
            {
                "arm_group_label": "GS-5737", 
                "arm_group_type": "Active Comparator", 
                "description": "The GS-5737 85 \u03bcg dose is contained in 4 mL of 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline."
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The vehicle control contains 10 mM citrate buffer, pH 5.0 in 2.8% (w/v) saline in 4 mL."
            }
        ], 
        "brief_summary": {
            "textblock": "This study will determine the safety, tolerability, and pharmacokinetics of a single dose of\n      GS-5737 administered with a 2.8% saline solution vehicle in adult subjects with CF."
        }, 
        "brief_title": "Phase 1b Safety, Tolerability, and PK Study to Assess GS-5737 in Subjects With CF", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": "Cystic Fibrosis", 
        "condition_browse": {
            "mesh_term": [
                "Cystic Fibrosis", 
                "Fibrosis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females, \u2265 18 years of age, at Screening\n\n          -  Diagnosis of CF as determined by the 1997 CF Consensus Conference criteria, with at\n             least 1 of the following: Documented sweat chloride \u2265 60 mEq/L by quantitative\n             pilocarpine iontophoresis test OR Abnormal nasal transepithelial potential difference\n             (NPD) test OR Two well-characterized, disease-causing genetic mutations in the CF\n             transmembrane conductance regulator (CFTR) gene AND 1 or more accompanying clinical\n             features consistent with CF\n\n          -  FEV1 \u2265 40% and \u2264 90% predicted\n\n          -  BMI \u2265 19 and \u2264 30 kg/m2\n\n          -  Clinically stable with no evidence of significant new or acute respiratory symptoms\n\n          -  Chest radiograph without significant acute findings; or chest radiograph, CT, or MRI\n             obtained and interpreted within 90 days prior to enrollment, without acute findings\n             and no significant intercurrent illness; chronic, stable findings are allowed\n\n          -  History of lifetime smoking < 5 pack-years (ie, 1 pack per day x 1 year =\n\n             1 pack-year) and non-smokers of at least 60 days duration prior to Screening\n\n          -  Estimated creatinine clearance \u2265 80 mL/min at Screening\n\n          -  Negative drug tests; including alcohol\n\n          -  Hepatitis B, C, & HIV Negative\n\n          -  Surgically sterile or \u2265 12 months post-menopausal\n\n          -  Non-pregnant females\n\n        Exclusion Criteria:\n\n          -  Experienced symptoms of recent acute upper or lower respiratory tract infection or\n             acute pulmonary exacerbation requiring treatment within 2 weeks prior to Screening\n\n          -  Plasma potassium \u2265 5 mEq/L\n\n          -  Changes in chronic azithromycin use, bronchodilator (BD), dornase alfa, HS,\n             physiotherapy technique or regimen, antibiotics or corticosteroid medications within\n             28 days prior to Screening\n\n          -  History of sputum or throat swab culture yielding Burkholderia species within 2 years\n             of Screening"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "8", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01840735", 
            "org_study_id": "GS-US-234-0117"
        }, 
        "intervention": [
            {
                "arm_group_label": "GS-5737", 
                "intervention_name": "GS-5737", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "intervention_name": "Vehicle", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "CF", 
            "Cystic Fibrosis", 
            "PK"
        ], 
        "lastchanged_date": "August 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Orlando", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32806"
                }, 
                "name": "Compass Research Phase 1, LLC"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Single Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of GS-5737 in Subjects With Cystic Fibrosis", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "July 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Peak Plasma Concentration (Cmax) of GS-5737", 
            "safety_issue": "Yes", 
            "time_frame": "1 day"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01840735"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Gilead Sciences", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Gilead Sciences", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}